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Anna Hotowy1, Ewa Sawosz2, Lane Pineda1, Filip Sawosz1, Marta Grodzik2 and André Chwalibog1*Abstract
Nanoparticles of colloidal silver (AgNano) can influence gene expression. Concerning trials of AgNano application in
poultry nutrition, it is useful to reveal whether they affect the expression of genes crucial for bird development.
AgNano were administered to broiler chickens as a water solution in two concentrations (10 and 20 ppm). After
dissection of the birds, breast muscles and hearts were collected. Gene expression of FGF2 and VEGFA on the mRNA
and protein levels were evaluated using quantitative polymerase chain reaction and enzyme-linked immunosorbent
assay methods. The results for gene expression in the breast muscle revealed changes on the mRNA level
(FGF2 was up-regulated, P< 0.05) but not on the protein level. In the heart, 20 ppm of silver nanoparticles in
drinking water increased the expression of VEGFA (P< 0.05), at the same time decreasing FGF2 expression both on
the transcriptional and translational levels. Changes in the expression of these genes may lead to histological
changes, but this needs to be proven using histological and immunohistochemical examination of tissues. In
general, we showed that AgNano application in poultry feeding influences the expression of FGF2 and VEGFA genes
on the mRNA and protein levels in growing chicken.
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Nanoparticles of colloidal silver (AgNano) are small
enough to penetrate into the cell and subsequently into
the nucleus. Direct interaction between them and DNA
molecules or DNA-related proteins leads to alterations
in gene expression profiles [1]. Clear evidence exists that
AgNano can modify gene expression in animal models
both in vivo and in vitro [2-5]. Taking into account the
first trials of silver nanoparticle application in poultry
production as an antimicrobial and nutritional agent [6],
it is necessary to evaluate their effects on gene expres-
sion. From a nutritional point of view, it would be inter-
esting to investigate genes with a crucial meaning for the
muscle development in birds. We have focused on two
genes, namely basic fibroblast growth factor 2 (FGF2)
and vascular endothelial growth factor A (VEGFA).* Correspondence: ac@life.ku.dk
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in any medium, provided the original work is pFGF2 consists of low and high molecular weight pro-
tein isoforms, localised to different cellular compart-
ments, indicating unique biological activity in vivo and
in vitro [7,8]. It has mitogenic activity on a variety of
mesodermal cells, including myoblasts [9]. FGF2 is im-
plicated in early vertebrate embryogenesis [10] and tis-
sue regeneration [11]. The immunolocalisation of FGF2
demonstrates that the spatial pattern of FGF2 localisa-
tion is highly specific. In the developing chick embryo,
FGF2 has been localised in the myocardium, the somite
myotome and limb bud muscles [12]. Experiments in
pigs also suggest that FGF2 might be involved in skeletal
muscle development during foetal and early postnatal
life [13]. In the heart, FGF2 isoforms have distinct roles
in many pathological conditions, including cardiac hy-
pertrophy, ischemia-reperfusion injury and atheroscler-
osis [7].
VEGFA is essential for early development of the vascu-
lature to the extent that inactivation of even a single al-
lele of the VEGFA gene results in embryonic lethality
[14,15]; furthermore, VEGFA is essential in regulatingan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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cles of adult VEGFA-deficient animals exhibit a major
intolerance to aerobic exercise [16].
Moreover, VEGFA positively influences dystrophic
skeletal muscle repair, improving their vascularity and
endogenous regeneration while lowering fibrosis; how-
ever, its uncontrolled expression causes unfavourable
changes in muscle morphology [17,18]. VEGFA exerts
action not only locally. It can mobilise endothelial pro-
genitor cells from the bone marrow even to distant sites
of neovascularisation [19].
Nutrition, in the case of poultry, can also comprise in
ovo feeding that can stimulate intestinal development by
enhancing villi development, thus increasing the intes-
tinal capacity to digest and absorb nutrients, which pro-
vides a basis for muscle growth [20]. Moreover, both
VEGFA and FGF2 injected into the vitelline vein of the
chicken embryo stimulate myocardial vascularization,
each of the proteins in a different way [21].
Few studies can be found on FGF2 and VEGFA ex-
pression, and their action in chicken embryos [12,21],
but there is no information whether AgNano can affect
expression of these genes in embryonic and growing
chicken as well. The purpose of this study was to assess
the influence of AgNano delivered in ovo and in vivo on
the expression of the abovementioned genes in chicken
and to indicate further research directions, which could
reveal possible AgNano applications.
Methods
Experiments, conducted during the prenatal and postna-
tal growth periods of broiler chickens, were carried out
in accordance with the Animal Experimentation Act in
Denmark (Law No. 726, September 1993).
Nanoparticles
The hydrocolloid of AgNano (Nano-Tech, Warsaw, Poland)
was produced by a patented non-explosive high-voltage
method from high-purity metals (99.9999%) and high-
purity demineralised water. The colloid contained 50 ppm
of Ag nanoparticles, with a particle size ranging from 2 to 6
nm, based on transmission electron microscope (TEM)
evaluation as described by Chwalibog et al. [22]. Experi-
mental drinking water solutions used in the experiments
were prepared by diluting the original concentration of the
AgNano solution (50 ppm) in distilled water. The concen-
trations were selected based on effective dose recorded
in weanling pigs (20 ppm of AgNano) [23] and in broilers
(10 ppm; LP, unpublished data), and on economically rele-
vant level.
In ovo treatments
Fertile eggs from Ross × Ross 308 breeder hens were
obtained from a commercial hatchery and transported tothe experimental farm of the University of Copenhagen.
Upon arrival, the eggs were numbered, weighed and
consequently treated according to the following descrip-
tions: (1) non-injected control (n= 240), (2) AgNano in-
jected (10 ppm of colloidal AgNano, n= 96) and (3)
AgNano injected (20 ppm of colloidal AgNano, n= 96).
The eggs were injected with 0.3 ml of the AgNano solu-
tions (10 or 20 ppm) into the air sac at the blunt end of
the albumen using sterile 1-ml tuberculin syringes with
a 27-gauge needle. Before and after the injection, the
shell was disinfected with ethanol. Afterwards, the hole
was sealed with hypoallergenic tape and the eggs were
placed in an incubator. The eggs were incubated for 21
days under standard conditions (temperature 37.8°C,
55% humidity, turned once per hour during the first 18
days, and at a temperature of 37°C and 60% humidity
from day 19 until hatching).
In vivo treatments
For the post-hatching experiment, five groups of 48
chickens were formed. Three groups were created from
the non-injected control group, and two additional groups
were formed from the groups injected with 10 and 20
ppm of AgNano (Figure 1). Chicks for each group were
randomly selected.
After hatching, for the first 6 days, the chicks were
kept in pens furnished with a heating lamp. The tem-
perature inside the brooding pen was 30°C to 33°C, and
the lighting programwas 23L:1D (L = light, D = darkness).
The 6-day transition period was applied to assure that
the chicks get used to the environmental conditions be-
fore the actual experiment starts and to exclude a
change of these conditions as a potential, additional fac-
tor influencing the results.
On day 7, 24 chicks from each group were randomly
selected, weighed, leg banded and transferred to meta-
bolic cages (0.5 m× 0.5 m×0.5 m) with four birds per
cage allocated into six replications. The room tempera-
ture from 7 to 35 days was 22°C with the following light-
ing program: days 7 to 13, 20L:4D; days 14 to 20,
21L:3D; days 21 to 27, 22L:2D and days 28 to 35,
23L:1D.
Throughout the experiment, the birds were fed ad
libitum with a commercial diet. For the first 6 days after
hatching, they obtained a commercial mixture contain-
ing 18.5% crude protein, 4.4% crude fat, 5.0% crude fibre,
5.8% ash, 10.3 g/kg lysine, 4.1 g/kg methionine and 3.4
g/kg cysteine. In the following 4 weeks, they were given
another mixture containing 17.6% crude protein, 3.3%
crude fat, 3.8% crude fibre, 5.2% ash, 8.7 g/kg lysine,
4.1 g/kg methionine and 3.2 g/kg cysteine. Both mix-
tures were produced by DLG (Axelborg, Copenhagen,
Denmark). The birds had free access to water containing
0, 10 or 20 ppm of colloidal AgNano offered for 4 weeks
Figure 1 Experimental design. Red arrows indicate random selection of the birds after hatching, from the in ovo part (eggs not injected and
injected with AgNano) to the in vivo part (broilers treated with AgNano drinking solution) of the experiment.
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brooding period. The broilers' body weight, feed con-
sumption and water intake were recorded at the begin-
ning and end of each week starting at day 7 until 35
days of age.
Dissection procedure
After 4 weeks, the broilers were weighed and eutha-
nized and the samples were collected. The hearts were
weighed, and relative heart weight was calculated as the
heart weight divided by the body weight, expressed as
percentage.
Tissues were put into labelled cryo-tubes and immedi-
ately frozen in liquid nitrogen. Afterwards, all the tubes
with frozen organs belonging to the same broiler were
placed in one plastic bag labelled with the ID number of
the bird and stored in the deep freezer (−80°C) until fur-
ther analysis.
Gene expression on the mRNA level
Gene expression on the mRNA level was measured in
breast muscle and heart samples using quantitative poly-
merase chain reaction method. The tissues (breast
muscle and heart) were homogenised in TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) using TissueLyser II
(Qiagen, Venlo, Netherlands), and total RNA was ex-
tracted according to the manufacturer's instructions. The
RNA samples were purified using the SV Total RNAIsolation System (Promega, Fitchburg, WI, USA). The
total RNA concentration was measured using a Nano-
Drop ND 1000 Spectrophotometer (NanoDrop Tech-
nologies, Wilmington, DE, USA). Two micrograms of
total RNA were reverse transcribed using reverse tran-
scriptase (Promega), oligo-dT and random primers (TAG
Copenhagen A/S Symbion, Copenhagen, Denmark), after
which real-time PCR was performed with cDNAs and
gene-specific primer pairs (TAG Copenhagen A/S Sym-
bion; Table 1) mixed with LightCyclerW480 SYBR Green
I Master (Roche Diagnostics, Basel, Switzerland) using a
LightCyclerW480 system (Roche Diagnostics). The sam-
ples were first denatured for 5 min at 95°C and then
amplified using 45 cycles of 10 s at 95°C (denaturation),
10 s at 60°C to 62°C (annealing) and 9 s at 72°C (elong-
ation) followed by quantitation. The reaction was per-
formed in triplicate for each cDNA. For all analyses,
relative quantification was applied, and actin beta
(ACTB) and elongation factor 1 alpha 2 (EEF1A2) were
used as the housekeeping genes.
Gene expression on the protein level
To estimate protein expression, enzyme-linked immuno-
sorbent assay (ELISA) was applied. Samples from the con-
trol group receiving water and groups receiving 20 ppm
of AgNano were chosen. Samples of heart and muscle
tissues were homogenised in chilled RIPA buffer (Sigma-
Aldrich, St. Louis, MO, USA) mixed with protease and
Table 1 Primer sequences for the investigated genes
Gene symbol Gene IDa Size (bp) Primer sequence (5’ to 3’)
ACTB 396526 ca. 169 forward: GTCCACCTTCCAGCAGATGT
reverse: ATAAAGCCATGCCAATCTCG
EEF1A2 419244 ca. 85 forward: AGCAGACTTTGTGACCTTGCC
reverse: TGACATGAGACAGACGGTTGC
FGF2 396413 ca. 151 forward: GGCACTGAAATGTGCAACAG
reverse: TCCAGGTCCAGTTTTTGGTC
VEGFA 395909 ca. 194 forward: TGAGGGCCTAGAATGTGTCC
reverse: TCTTTTGACCCTTCCCCTTT
aNCBI resources.
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use with mammalian cell and tissue extracts, DMSO so-
lution, Sigma-Aldrich, and Phosphatase Inhibitor Cock-
tail 2, Sigma-Aldrich), using TissueLyser II (Qiagen).
Then, samples were kept at 4°C for 1 h while slowly mix-
ing. Afterwards, the samples were centrifuged at 4°C (30
min, 14,000 rpm). The supernatant was aliquoted into
Eppendorf tubes to avoid frequent freeze/thaw cycles and
frozen at −20°C. Each aliquot was used for determining
the protein concentration (Total Protein Kit, Micro-
Lowry, Peterson's Modification, Sigma-Aldrich) and for
ELISA tests on the same day.
Kits for gallinaceous Fibroblast Growth Factor 2 and
Vascular Endothelial Cell Growth Factor A (USCN Life
Science, Wuhan, China) were used. Reagents and plates
were prepared according to the manufacturer's instruc-
tions. The level of absorption was measured using an In-
finite M200 microplate reader (TECAN, Crailsheim,
Germany) at a wavelength of 450 nm. All samples were
measured in duplicate.
Statistical analysis
Analysis of the data was carried out using t-tests and
one-way analysis of variance (ANOVA) tests - general-
ized linear model procedure in SAS 9.2 (SAS Windows,
2002–2008, version 9.2, SAS Institute Inc., Cary, NC,
USA). Values differing at P< 0.05 were considered
significant.
Results
There were no significant differences in body weight,
heart weight and relative heart weight between experi-
mental groups (Table 2).
Gene expression
Breast muscle
The expression of FGF2, normalised to ACTB, was
higher in all treatment groups than in the control group;
however, differences between treatments were not sig-
nificant. Regarding EEF1A2, significant differences were
observed only between the control and the group whichobtained the higher dose (20 ppm) of AgNano in the
drinking water but had not been injected in ovo
(Table 3).
When VEGFA was examined, the level of expression
in the breast muscle was higher in the group that had
been injected in ovo and obtained 20 ppm of AgNano
in the drinking water, compared to both non-injected
groups receiving different solutions of AgNano in the
drinking water. At the same time, the expression of this
gene did not differ between the two injected groups and
the untreated control group receiving water (Table 3).
Heart
Regarding FGF2 expression levels in the heart, when
ACTB was used as the housekeeping gene, a significant
difference was observed between the control and the
group injected in ovo and treated with 20 ppm of
AgNano in the drinking water. The expression of FGF2
normalised to EEF1A2 revealed no significant differences
between the experimental groups (Table 4).
In the case of VEGFA normalised to ACTB, no signifi-
cant differences could be reported between the experi-
mental groups. The high level of AgNano (20 ppm)
given in the drinking water increased the expression of
VEGFA normalised to EEF1A2 in both the injected and
non-injected treatment groups (Table 4).
Protein expression
Concerning FGF2 and VEGFA on the protein level, no
significant differences were found between treatments in
the muscle tissue (Figure 2).
In the heart, the level of FGF2 protein after AgNano
administration was lower, whereas the level of VEGFA
protein was higher in the group treated with 20 ppm of
AgNano, compared to the control group (Figure 3).
Discussion
Due to the tissue specificity of the reference genes
[24-27], the results for each examined target gene are not
identical relative to the individual reference genes (espe-
cially in the heart). However, for both housekeeping
Table 2 Body and heart weight of chickens treated with different levels of AgNano
Weight Treatment ANOVA
Control 10 ppm AgNano 20 ppm AgNano 10 ppm AgNanob 20 ppm AgNanob SEM P value
Body (kg) 1.578 1.684 1.725 1.436 1.545 0.0455 0.2853
Heart (g) 6.52 7.00 6.80 6.14 6.23 0.299 0.8937
Hearta (relative, %) 0.407 0.413 0.392 0.427 0.406 0.0124 0.9427
aValues were calculated as the heart weight divided by the body weight, expressed as percentage; beggs were in ovo injected; the level of significance is P< 0.05.
AgNano, nanoparticles of colloidal silver; ANOVA, analysis of variance; SEM, standard error of the mean.
Hotowy et al. Nanoscale Research Letters 2012, 7:418 Page 5 of 8
http://www.nanoscalereslett.com/content/7/1/418genes, the relative levels of target gene expression pre-
sented almost the same pattern of changes.
Our results suggest that, in the case of chicken breast
muscle tissue, oral AgNano administration influences
FGF2 and VEGFA expression on the mRNA level, with-
out leading to changes on the protein level. It could be
suspected, at least in the case of FGF2, that such a dif-
ference might be caused by an unspecific isoform of this
protein. Currently, only low molecular weight recombin-
ant FGF2 protein is available on the market. However,
the FGF2 antibody is not differentially specific against
the two isoforms [7]. Assuming this, our results could
mean that all the histological changes (like multipotent
mesenchymal cell differentiation, satellite cell prolifera-
tion and angiogenesis) that have been noted in previous
in vitro and in vivo studies [28-32] should not be ex-
pected in our case, or at least may not be caused directly
by changes of FGF2 and VEGFA protein expression. This
effect could be considered beneficial in terms of angio-
genesis, which is a fundamental process affecting tumour
growth and metastasis [19,33-37]. Nevertheless, this re-
mains to be clarified by applying histological and immu-
nohistochemical methods of examination of the tissue.
The opposite effect of AgNano administration was
observed in the case of the cardiac muscle, where, with-
out any impact on relative heart weight (Table 2), the ex-
pression of both genes was affected.
FGF2 expression on the mRNA level was down-
regulated in the in ovo injected group which obtained 20
ppm of AgNano in the drinking water, compared to the
control group. Similar results were noted regarding pro-
tein expression, where the FGF2 level was lower in the
AgNano-treated group compared to the control group.




Control 10 ppm AgNano 20 ppm AgNano
FGF2a 0.67† 1.28{ 1.44{
FGF2b 0.60† 0.98 1.38{
VEGFAa 1.39 1.08† 1.03†
VEGFAb 1.28 1.02† 0.95†
aNormalised to ACTB; bnormalised to EEF1A2; ceggs were in ovo injected; †,{different
nanoparticles of colloidal silver; ANOVA, analysis of variance; SEM, standard error ofagreement with the findings of Bougioukas et al. [38],
which suggested possible neovascularisation in the heart
caused by this protein. However, according to another
study, the expression of this gene remains unchanged
during angiogenesis caused by bradycardia, suggesting
that FGF2 does not play a direct role in this process
[14]. On the other hand, some evidence exists that FGF2
(the high molecular weight isoform) can prevent endo-
thelial cell migration and angiogenesis [39] and promote
cardiac myocyte hypertrophy [40-42]. From this point of
view, our findings may support possible targeted therap-
ies with AgNano application.
It has been shown that VEGFA mRNA and protein are
increased in the muscle during angiogenesis caused by
repeated exercise [43-45]. Also, the mechanisms asso-
ciated with bradycardia provide a signal for the enhance-
ment of VEGFA expression, which is responsible for the
myocardial angiogenesis [46]. We have demonstrated
that AgNano at a concentration of 20 ppm administered
to broiler chickens in the drinking water caused up-
regulation of VEGFA expression in the heart on the
mRNA and protein level. VEGFA modulates angiogen-
esis in dystrophic muscle [17,18] and in the heart
[21,46]. To reveal whether AgNano might influence the
heart angiogenesis in our experiment, resulting in the
neovascularisation of the cardiac muscle, histological
examination of the tissue should be performed.
Recent data indicate that regulation of VEGFA and
FGF2 expression occurs on the transcriptional as well as
translational levels, depending on the tissue and cell type
[8,33-35,47,48]. Our results support these findings,
showing that VEGFA and FGF2 expression can be regu-
lated pre- and post-transcriptionally. Transcriptional and
translational regulation of gene expression comprises theens treated with different levels of AgNano
ANOVA
10 ppm AgNanoc 20 ppm AgNanoc SEM P value
1.05{ 1.23{ 0.070 0.0003
0.95 0.93 0.068 0.0024
1.13 1.60{ 0.064 0.0057
1.01 1.28{ 0.055 0.0072
symbols indicate statistically significant differences (P < 0.05). AgNano,
the mean.




Control 10 ppm AgNano 20 ppm AgNano 10 ppm AgNanoc 20 ppm AgNanoc SEM P value
FGF2a 0.97† 0.85 0.79 0.84 0.69{ 0.028 0.0443
FGF2b 1.47 1.32 1.34 1.15 1.31 0.054 0.5839
VEGFAa 0.59 0.68 0.78 0.73 0.61 0.026 0.0888
VEGFAb 0.75† 0.93 1.12{ 0.84 1.14{ 0.044 0.0027
aNormalised to ACTB; bnormalised to EEF1A2; ceggs were in ovo injected; †,{different symbols indicate statistically significant differences (P < 0.05). AgNano,
nanoparticles of colloidal silver; ANOVA, analysis of variance; SEM, standard error of the mean.
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molecules, including DNA, proteins, mRNAs and miR-
NAs [49-51]. Our results demonstrate that, in the case
of FGF2 expression in the muscle, regulatory mechan-
isms prevent the increase of the level of the protein
product of the gene.
Experimental data show that in ovo treatment can pro-
vide a basis for muscle growth and stimulate coronary de-
velopment [20,21]. However, some of our unpublished
data suggest that AgNano injected in ovo at early stages of
the embryonic development seem not to evoke long-
lasting influence on gene expression, which is prolonged
after the hatching period. Therefore, our aim was rather
to observe whether in ovo injection could change the ef-
fect of AgNano distributed with drinking water. Answer-
ing this question, we assumed that indeed, in ovo injection
up-regulated both the heart expression of FGF2 as well as
the muscle expression of VEGFA in broilers treated with
drinking solution of 20 ppm of AgNano. However, the
AgNano drinking solution itself (both concentrations)
evoked up-regulation of FGF2 expression in the muscle,
without enhancing the effect of in ovo injection.
Changes in the expression of investigated genes on the
protein level may lead to harmful or beneficial histological
changes. When examining silver residues in organs after
AgNano administration, our unpublished results have
shown minor Ag deposition in the breast muscle tissueFigure 2 Protein expression in the breast muscle. The vertical
axis shows the concentration of the target protein in picograms per
milligram of total protein (TP). Error bars indicate standard deviation
(SD). The level of significance is P< 0.05.and very slight deposition in the hearts of birds treated
with a 20-ppm solution of colloidal silver, compared to the
control group. However, these results could not inform us
regarding the form of Ag deposited in the tissues. Sup-
porting data from histological and TEM examinations of
these tissues are needed to elucidate whether AgNano or
rather silver ions exert a direct action.
Conclusions
AgNano application in poultry feeding can significantly
influence the expression of FGF2 and VEGFA genes on
the mRNA and protein levels in growing chicken. In ovo
injection of AgNano at early embryonic stages of the de-
velopment can enhance the effect of AgNano, distributed
as a drinking solution, on FGF2 and VEGFA expression.
On the protein level, AgNano influence FGF2 and
VEGFA expression only in the heart, whereas in the
muscle, the level of FGF2 and VEGFA protein remains
unchanged. Supporting data from histological and TEM
examinations of these tissues are needed to elucidate
whether AgNano or rather silver ions exert a direct ac-
tion on gene expression, and whether AgNano could
evoke neovascularisation in the heart.
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